{"id":49485,"date":"2025-11-29T21:35:31","date_gmt":"2025-11-29T13:35:31","guid":{"rendered":"https:\/\/flcube.com\/?p=49485"},"modified":"2025-11-29T21:35:32","modified_gmt":"2025-11-29T13:35:32","slug":"genscis-gensci142-wins-nmpa-nod-for-bacterial-vaginosis-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49485","title":{"rendered":"GenSci&#8217;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials"},"content":{"rendered":"\n<p><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced that its subsidiary <strong>GenSci (GeneScience Pharmaceutical)<\/strong> received <strong>clinical trial approval<\/strong> from the <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>GenSci142 Capsule<\/strong>, a <strong>Category\u202f1 biological product<\/strong> for the <strong>treatment of bacterial vaginosis (BV)<\/strong>, leveraging an <strong>AI\u2011optimized molecular structure<\/strong> that selectively kills pathogens while preserving protective lactobacilli.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>GenSci142 Capsule<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>GenSci (GeneScience Pharmaceutical), subsidiary of Changchun High\u2011Tech (000661.SZ)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval (Category\u202f1 biological product)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Bacterial vaginosis (BV)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>AI\u2011optimized antimicrobial; preserves lactobacilli; penetrates biofilms<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Initiate Phase\u202fI\/II study Q2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Directly disrupts bacterial cell wall, <strong>selectively and rapidly killing primary BV pathogens<\/strong> while <strong>fully preserving protective lactobacilli<\/strong><\/li>\n\n\n\n<li><strong>Biofilm Penetration:<\/strong> Can <strong>penetrate and dismantle biofilms<\/strong>, eliminating pathogen reservoirs and reducing recurrence risk<\/li>\n\n\n\n<li><strong>Clinical Response:<\/strong> Potential to <strong>significantly alleviate symptoms within 12 hours<\/strong><\/li>\n\n\n\n<li><strong>Resistance Profile:<\/strong> Remains effective against <strong>metronidazole\u2011resistant infections<\/strong> (90% resistance rate)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Local vaginal delivery<\/strong>, no systemic exposure, safe for use<\/li>\n\n\n\n<li><strong>AI Optimization:<\/strong> Utilizes <strong>bioinformatics screening<\/strong> and <strong>AI\u2011driven molecular structure optimization<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China BV Patients<\/strong><\/td><td>~<strong>30\u202fmillion<\/strong> women annually (2024)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Metronidazole\/clindamycin (80% share); 30\u201150% recurrence rate<\/td><\/tr><tr><td><strong>Metronidazole Resistance<\/strong><\/td><td><strong>90%<\/strong> in some regions<\/td><\/tr><tr><td><strong>BV Treatment Market Size (China)<\/strong><\/td><td>\u00a54.2\u202fbillion (US$580\u202fmillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>9% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (GenSci142)<\/strong><\/td><td><strong>\u00a52.0\u20112.8\u202fbillion<\/strong> (~US$270\u2011380\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>15\u201120% of metronidazole\u2011resistant or recurrent BV segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> No approved <strong>non\u2011antibiotic BV therapies<\/strong> in China; GenSci142\u2019s <strong>lactobacillus\u2011sparing<\/strong> and <strong>biofilm\u2011penetrating<\/strong> mechanism offers <strong>first\u2011in\u2011class differentiation<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement Path:<\/strong> NMPA Category\u202f1 status qualifies for <strong>Priority Review<\/strong>; potential NRDL inclusion based on <strong>superior efficacy vs. standard of care<\/strong><\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Expands Changchun High\u2011Tech\u2019s <strong>biologics portfolio<\/strong> beyond growth hormone; validates <strong>AI\u2011driven drug discovery platform<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GenSci142\u2019s clinical development, regulatory pathway, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the women\u2019s health market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci142\u80f6\u56ca\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci142\u80f6\u56ca\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-df8f6a11-8d90-4d64-b7d1-cc820c7c7c18\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci142\u80f6\u56ca\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci142\u80f6\u56ca\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci142\u80f6\u56ca\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-df8f6a11-8d90-4d64-b7d1-cc820c7c7c18\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49489,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,4422,1171],"class_list":["post-49485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-gensciences","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenSci&#039;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49485\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSci&#039;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49485\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-29T13:35:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-29T13:35:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenSci&#8217;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials\",\"datePublished\":\"2025-11-29T13:35:31+00:00\",\"dateModified\":\"2025-11-29T13:35:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805-1.webp\",\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"Gensciences\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49485#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49485\",\"name\":\"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805-1.webp\",\"datePublished\":\"2025-11-29T13:35:31+00:00\",\"dateModified\":\"2025-11-29T13:35:32+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49485\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49485#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSci&#8217;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49485","og_locale":"en_US","og_type":"article","og_title":"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.","og_url":"https:\/\/flcube.com\/?p=49485","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-29T13:35:31+00:00","article_modified_time":"2025-11-29T13:35:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49485#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49485"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenSci&#8217;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials","datePublished":"2025-11-29T13:35:31+00:00","dateModified":"2025-11-29T13:35:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49485"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49485#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","Gensciences","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49485#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49485","url":"https:\/\/flcube.com\/?p=49485","name":"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49485#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49485#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","datePublished":"2025-11-29T13:35:31+00:00","dateModified":"2025-11-29T13:35:32+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci (GeneScience Pharmaceutical) received clinical trial approval from the National Medical Products Administration (NMPA) for GenSci142 Capsule, a Category\u202f1 biological product for the treatment of bacterial vaginosis (BV), leveraging an AI\u2011optimized molecular structure that selectively kills pathogens while preserving protective lactobacilli.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49485#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49485"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49485#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","width":1080,"height":608,"caption":"GenSci's GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49485#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenSci&#8217;s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49485"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49485\/revisions"}],"predecessor-version":[{"id":49490,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49485\/revisions\/49490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49489"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}